Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Time for a systematic look at inactivated HIV vaccines.

Sheppard HW, Dorman BP.

AIDS. 2015 Jan 2;29(1):125-7. doi: 10.1097/QAD.0000000000000476. No abstract available.

PMID:
25562497
2.

Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection.

Planque S, Mitsuda Y, Taguchi H, Salas M, Morris MK, Nishiyama Y, Kyle R, Okhuysen P, Escobar M, Hunter R, Sheppard HW, Hanson C, Paul S.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1541-54.

PMID:
18160012
3.

Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.

Rademeyer C, Moore PL, Taylor N, Martin DP, Choge IA, Gray ES, Sheppard HW, Gray C, Morris L, Williamson C; HIVNET 028 study team.

Virology. 2007 Nov 10;368(1):172-81. Epub 2007 Jul 16.

4.

HIV type 1 subtype C gag and nef diversity in Southern Africa.

Bredell H, Martin DP, Van Harmelen J, Varsani A, Sheppard HW, Donovan R, Gray CM; HIVNET028 Study Team, Williamson C.

AIDS Res Hum Retroviruses. 2007 Mar;23(3):477-81.

PMID:
17411382
5.

Breast milk pasteurization: appropriate assays to detect HIV inactivation.

Chantry CJ, Abrams BF, Donovan RM, Israel-Ballard KA, Sheppard HW.

Infect Dis Obstet Gynecol. 2006;2006:95938. No abstract available.

6.

Sequential turnover of human immunodeficiency virus type 1 env throughout the course of infection.

Riddle TM, Shire NJ, Sherman MS, Franco KF, Sheppard HW, Nelson JA.

J Virol. 2006 Nov;80(21):10591-9. Epub 2006 Sep 6.

7.

Heat treating breast milk as an infant feeding option.

Israel-Ballard KA, Chantry CJ, Dewey KG, Donovan RM, Sheppard HW, Abrams BF.

J Hum Lact. 2006 Aug;22(3):267-8; author reply 268. No abstract available.

PMID:
16885483
8.

Inactivated- or killed-virus HIV/AIDS vaccines.

Sheppard HW.

Curr Drug Targets Infect Disord. 2005 Jun;5(2):131-41. Review.

PMID:
15975019
9.

Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa.

Gray CM, Williamson C, Bredell H, Puren A, Xia X, Filter R, Zijenah L, Cao H, Morris L, Vardas E, Colvin M, Gray G, McIntyre J, Musonda R, Allen S, Katzenstein D, Mbizo M, Kumwenda N, Taha T, Karim SA, Flores J, Sheppard HW.

AIDS Res Hum Retroviruses. 2005 Apr;21(4):285-91.

PMID:
15943570
10.

Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in Sao Paulo, Brazil, from 1991 to 2002.

de Freitas Oliveira CA, Ueda M, Yamashiro R, Rodrigues R, Sheppard HW, de Macedo Brígido LF.

J Clin Microbiol. 2005 Mar;43(3):1439-42.

11.

Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa.

Masemola AM, Mashishi TN, Khoury G, Bredell H, Paximadis M, Mathebula T, Barkhan D, Puren A, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Karim SA, Sheppard HW, Gray CM; HIVNET 028 Study Team.

J Immunol. 2004 Oct 1;173(7):4607-17.

12.

Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1.

Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai LO, Hirunras K, Kitayaporn D, Kaewkangwal J, Migasena S, Sheppard HW, Li E, Chernow M, Peterson ML, Shibata R, Heyward WL, Francis DP.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1160-5. Erratum in: J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1669.

PMID:
15319676
13.

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.

Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL.

J Infect Dis. 2004 Sep 1;190(5):903-7. Epub 2004 Jul 29.

PMID:
15295694
14.

Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load.

Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Karim SA, Sheppard HW, Gray CM; HIVNET 028 Study Team.

J Virol. 2004 Apr;78(7):3233-43.

15.

High incidence and prevalence of HIV-1 infection in high risk population in Calcutta, India.

Gupta P, Kingsley L, Sheppard HW, Harrison LH, Chatterjee R, Ghosh A, Roy P, Neogi DK.

Int J STD AIDS. 2003 Jul;14(7):463-8.

PMID:
12869226
16.

Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection.

Rawal BD, Degula A, Lebedeva L, Janssen RS, Hecht FM, Sheppard HW, Busch MP.

J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):349-55.

PMID:
12843746
17.

Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.

Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, Jamieson BD, Meyer L, Michael NL, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Theodorou ID, Vlahov D, Rosenberg PS; International Meta-Analysis of HIV Host Genetics.

AIDS. 2003 Feb 14;17(3):377-87.

PMID:
12556692
18.

High incidence of HIV-1 in South Africa using a standardized algorithm for recent HIV seroconversion.

Gouws E, Williams BG, Sheppard HW, Enge B, Karim SA.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):531-5.

PMID:
11981371
19.

HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.

Sheppard HW, Celum C, Michael NL, O'Brien S, Dean M, Carrington M, Dondero D, Buchbinder SP.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):307-13. Review.

PMID:
11873082
20.

Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.

Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA, Eugen-Olsen J, Gallart T, Katzenstein TL, Kostrikis LG, Kuipers H, Louie LG, Mallal SA, Margolick JB, Martinez OP, Meyer L, Michael NL, Operskalski E, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Stewart GJ, Theodorou ID, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury JF, O'Brien TR; International Meta-Analysis of HIV Host Genetics.

Ann Intern Med. 2001 Nov 6;135(9):782-95.

PMID:
11694103
21.

Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates.

Lee SA, Orque R, Escarpe PA, Peterson ML, Good JW, Zaharias EM, Berman PW, Sheppard HW, Shibata R.

Vaccine. 2001 Nov 12;20(3-4):563-76.

PMID:
11672923
22.

Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection.

Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, Koblin B, Seage GR 3rd; HIV Network for Prevention Trials Vaccine Preparedness Protocol Team.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):472-81.

PMID:
11511825
23.

Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.

Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, Marmor M, Bozeman S, Grant RM, Flores J, Sheppard HW.

J Infect Dis. 2001 Jan 1;183(1):23-35. Epub 2000 Dec 8.

PMID:
11106536
24.

Limitations of plasma human immunodeficiency virus RNA testing.

Krowka JF, Sheppard HW, Ascher MS, Hallowitz R.

Clin Infect Dis. 2000 Nov;31(5):1317-8. No abstract available.

PMID:
11073782
25.

CCR2-64I polymorphism, syncytium-inducing human immunodeficiency virus strains, and disease progression.

Vicenzi E, Ghezzi S, Brambilla A, Sheppard HW, Lazzarin A, Poli G, Michael NL.

J Infect Dis. 2000 Nov;182(5):1579-80. No abstract available.

PMID:
11023492
26.

Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil. Projeto Praço Onze Study Group.

Schechter M, do Lago RF, de Melo MF, Sheppard HW, Guimarães NC, Moreira RI, Faulhaber JC, Batista S, Harrison LH.

J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):175-7.

PMID:
10935694
27.

Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection.

Brambilla A, Villa C, Rizzardi G, Veglia F, Ghezzi S, Lazzarin A, Cusini M, Muratori S, Santagostino E, Gringeri A, Louie LG, Sheppard HW, Poli G, Michael NL, Pantaleo G, Vicenzi E.

J Infect Dis. 2000 Jul;182(1):311-5. Epub 2000 Jul 6.

PMID:
10882614
28.

Dissociation of immunologic and virologic responses to highly active antiretroviral therapy.

Fessel WJ, Krowka JF, Sheppard HW, Gesner M, Tongson S, Weinstein S, Ascher M, Kwok S, Christopherson C.

J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):314-20.

PMID:
10836753
29.

Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination.

Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC.

J Virol. 1999 Jan;73(1):152-60.

30.

CXCR4 polymorphisms and HIV-1 pathogenesis.

Martin MP, Carrington M, Dean M, O'Brien SJ, Sheppard HW, Wegner SA, Michael NL.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):430. No abstract available.

PMID:
9833755
31.

Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection.

Loomis-Price LD, Cox JH, Mascola JR, VanCott TC, Michael NL, Fouts TR, Redfield RR, Robb ML, Wahren B, Sheppard HW, Birx DL.

J Infect Dis. 1998 Nov;178(5):1306-16.

PMID:
9780250
32.

Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.

Wilson SE, Pedersen SL, Kunich JC, Wilkins VL, Mann DL, Mazzara GP, Tartaglia J, Celum CL, Sheppard HW.

AIDS Res Hum Retroviruses. 1998 Jul 20;14(11):925-37.

PMID:
9686639
33.

Transmission of genetically diverse strains of HIV-1 in Pune, India.

Gadkari DA, Moore D, Sheppard HW, Kulkarni SS, Mehendale SM, Bollinger RC.

Indian J Med Res. 1998 Jan;107:1-9.

PMID:
9529774
34.

Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: a worst-case dynamic analysis.

Anderson RW, Ascher MS, Sheppard HW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):245-52. Review.

PMID:
9495225
35.

Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals.

Krowka JF, Gesner ML, Ascher MS, Sheppard HW.

Clin Immunol Immunopathol. 1997 Oct;85(1):21-7.

PMID:
9325065
36.

The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression.

Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE, Sheppard HW.

Nat Med. 1997 Oct;3(10):1160-2.

PMID:
9334732
37.

Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS.

Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, Korber B, Mullins JI.

J Virol. 1997 Oct;71(10):7498-508.

38.

CCR5-delta 32 gene deletion in HIV-1 infected patients.

Michael NL, Louie LG, Sheppard HW.

Lancet. 1997 Sep 6;350(9079):741-2. No abstract available.

PMID:
9291931
39.

The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression.

Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW.

Nat Med. 1997 Mar;3(3):338-40.

PMID:
9055864
40.

Immunotherapy for HIV.

Krowka JF, Sheppard HW, Ascher MS.

Lancet. 1997 Feb 8;349(9049):434. No abstract available.

PMID:
9033497
41.

The lack of association of marijuana and other recreational drugs with progression to AIDS in the San Francisco Men's Health Study.

Di Franco MJ, Sheppard HW, Hunter DJ, Tosteson TD, Ascher MS.

Ann Epidemiol. 1996 Jul;6(4):283-9.

PMID:
8876838
42.

Expression of CD69 after in vitro stimulation: a rapid method for quantitating impaired lymphocyte responses in HIV-infected individuals.

Krowka JF, Cuevas B, Maron DC, Steimer KS, Ascher MS, Sheppard HW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1;11(1):95-104.

PMID:
8528739
43.

Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression.

Michael NL, Chang G, d'Arcy LA, Tseng CJ, Birx DL, Sheppard HW.

J Virol. 1995 Nov;69(11):6758-69.

44.

Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual.

Iversen AK, Shpaer EG, Rodrigo AG, Hirsch MS, Walker BD, Sheppard HW, Merigan TC, Mullins JI.

J Virol. 1995 Sep;69(9):5743-53.

45.

HIV results in the frame. Paradox remains.

Ascher MS, Sheppard HW, Anderson RW, Krowka JF, Bremermann HJ.

Nature. 1995 May 18;375(6528):196; author reply 198. No abstract available.

PMID:
7746317
46.

Response.

Ascher MS, Sheppard HW, Winkelstein W Jr.

Science. 1995 Apr 21;268(5209):351-2. No abstract available.

PMID:
17746529
47.

AIDS-associated Kaposi's sarcoma. "Duesberg phenomenon'.

Ascher MS, Sheppard HW.

Science. 1995 Feb 24;267(5201):1080. No abstract available.

PMID:
7726989
48.

AIDS as immune system activation. Key questions that remain.

Ascher MS, Sheppard HW, Krowka JF, Bremermann HJ.

Adv Exp Med Biol. 1995;374:203-10. Review.

PMID:
7572393
49.

HIV infection in homosexual and bisexual men 18 to 29 years of age: the San Francisco Young Men's Health Study.

Osmond DH, Page K, Wiley J, Garrett K, Sheppard HW, Moss AR, Schrager L, Winkelstein W.

Am J Public Health. 1994 Dec;84(12):1933-7.

50.

Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays.

Delwart EL, Sheppard HW, Walker BD, Goudsmit J, Mullins JI.

J Virol. 1994 Oct;68(10):6672-83.

Supplemental Content

Loading ...
Support Center